| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2026―Mar―05 |
The number of newly dispensed anxiolytic and antidepressant drugs during the first COVID-19 lockdown period in the Netherlands: Sex- and age-specific trends |
Pantea Kiani, Pauline A. Hendriksen, Dana M. Dijkgraaf, Maureen N. Zijlstra, Johan Garssen, Joris C. Verster |
| 2 |
[GO] |
2025―Apr―17 |
Discovery of Cinnamoyl-Flavonoid Hybrid Derivatives as Inhibitors of SARS-CoV-2 Mpro and Anti-inflammatory Agents: Experimental and In Silico Insights into their Efficacy against Lipopolysaccharide-Induced Lung Injury |
Kraikrit Utama, Nopawit Khamto, Atchara Janthong, Chanidapha Thiraphatchotiphum, Sittiruk Roytrakul, Jiraporn Kantapan, Puttinan Meepowpan, Padchanee Sangthong |
| 3 |
[GO] |
2025―Mar―26 |
Iguratimod, a Promising Therapeutic Agent for COVID-19 that Attenuates Excessive Inflammation in Mouse Models |
Seiya Oba, Tadashi Hosoya, Daisuke Kawata, Yoji Komiya, Hideyuki Iwai, Ryuji Koike, Sho Miyamoto, Takayuki Kanno, Akira Ainai, Tadaki Suzuki, Hideki Hasegawa, Shinsuke Yasuda |
| 4 |
[GO] |
2024―Sep―18 |
Harringtonine metabolites: 5'-de-O-methylharringtonine and cephalotaxine, targeting spike protein and TMPRSS2 to double block membrane fusion of SARS-CoV-2 and its variants |
Jiapan Gao, Shiling Hu, Xiaoyu Ma, Yuxiu Zhang, Bingxi Ren, Panpan Lei, Weina Ma, Langchong He |
| 5 |
[GO] |
2024―Apr―12 |
Corrigendum to “The prophylaxis and treatment potential of supplements for COVID-19” [Eur. J. Pharmacol. 887 (15 November 2020) 173530] |
Adeleh Sahebnasagh, Fatemeh Saghafi, Razieh Avan, Amirhosein Khoshi, Masoud Khataminia, Mohammadreza Safdari, Solomon Habtemariam, Hassan Rezai Ghaleno, Seyed Mohammad Nabavi |
| 6 |
[GO] |
2023―Sep―27 |
From cardiovascular system to brain, the potential protective role of mas receptors in COVID-19 infection. |
Pamela Cappelletti, Giovanna Gallo, Rachele Marino, Sakthimala Palaniappan, Massimo Corbo, Carmine Savoia, Marco Feligioni |
| 7 |
[GO] |
2023―Jan―30 |
The role of the glucocorticoid receptor and its impact on steroid response in moderate-severe COVID-19 patients |
Gestina Aliska, Nafrialdi Nafrialdi, Khie Chen Lie, Rianto Setiabudy, Andani Eka Putra, Indah Suci Widyahening, Alida Roswita Harahap |
| 8 |
[GO] |
2023―Jan―12 |
Risk of thromboembolic events in non-hospitalized COVID-19 patients: A systematic review |
Gaelle P. Massoud, Dana H. Hazimeh, Ghadir Amin, Wissam Mekary, Joanne Khabsa, Tarek Araji, Souha Fares, Mathias Mericskay, George W. Booz, Fouad A. Zouein |
| 9 |
[GO] |
2022―Nov―15 |
Therapeutic role of N-acetyl cysteine (NAC) for the treatment and/or management of SARS-CoV-2-induced lung damage in hamster model |
Voddu Suresh, Padmanava Behera, Deepti Parida, Amlan Priyadarshee Mohapatra, Suraja Kumar Das, Sneha Kumari, Kiran Avula, Amruta Mohapatra, Gulam Hussain Syed, Shantibhusan Senapati |
| 10 |
[GO] |
2022―Sep―17 |
Immunomodulatory role of Nanocurcumin in COVID-19 patients with dropped natural killer cells frequency and function |
Sanaz Abbaspour-Aghdam, Ali Hazrati, Samaneh Abdolmohammadi-Vahid, Safa Tahmasebi, Jafar Mohseni, Hamed Valizadeh, Mehdi Nadiri, Haleh Mikaeili, Armin Sadeghi, Mehdi Yousefi, Leila Roshangar, Behzad Nikzad, Farhad Jadidi-Niaragh, Hossein Samadi Kafil, Kosar Malekpour, Majid Ahmadi |
| 11 |
[GO] |
2022―Jul―31 |
Mast cells promote viral entry of SARS-CoV-2 via formation of chymase/spike protein complex |
Shuang Liu, Yasuyuki Suzuki, Erika Takemasa, Ryusuke Watanabe, Masaki Mogi |
| 12 |
[GO] |
2022―May―23 |
Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019 |
Hossein Khorramdelazad, Mohammad Hossein Kazemi, Maryam Azimi, Azin Aghamajidi, Ali Zarezadeh Mehrabadi, Faezeh Shahba, Nazanin Aghamohammadi, Reza Falak, Fatemeh Faraji, Reza Jafari |
| 13 |
[GO] |
2021―Dec―02 |
The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial |
Mojtaba Shohan, Roohangiz Nashibi, Mohammad-Reza Mahmoudian-Sani, Farhad Abolnezhadian, Mehri Ghafourian, Seyed Mohammad Alavi, Asaad Sharhani, Ali Khodadadi |
| 14 |
[GO] |
2021―Oct―21 |
Use of steroids in COVID-19 patients: A meta-analysis |
Manisha Thakur, Ashok Kumar Datusalia, Anoop Kumar |
| 15 |
[GO] |
2021―Oct―21 |
Potential pharmacologic treatments for COVID-19 smell and taste loss: A comprehensive review |
Elnaz Khani, Sajad Khiali, Samineh Beheshtirouy, Taher Entezari-Maleki |
| 16 |
[GO] |
2021―Oct―02 |
Sex-related susceptibility in coronavirus disease 2019 (COVID-19): Proposed mechanisms |
Zinnet Şevval Aksoyalp, Dilara Nemutlu-Samur |
| 17 |
[GO] |
2021―Jul―22 |
SARS-CoV-2 attenuates corticosteroid sensitivity by suppressing DUSP1 expression and activating p38 MAPK pathway |
Fatemeh Saheb Sharif-Askari, Narjes Saheb Sharif-Askari, Swati Goel, Shirin Hafezi, Rasha Assiri, Saleh Al-Muhsen, Qutayba Hamid, Rabih Halwani |
| 18 |
[GO] |
2021―Jul―07 |
Effects of antiviral drug therapy on dynamic thiol/disulphide homeostasis and nitric oxide levels in COVID-19 patients |
Ayşe Özlem Mete, Kübra Koçak, Ahmet Saracaloglu, Seniz Demiryürek, Özgür Altınbaş, Abdullah T. Demiryürek |
| 19 |
[GO] |
2021―Jun―12 |
Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies |
Kiarash Saleki, Shakila Yaribash, Mohammad Banazadeh, Ehsan Hajihosseinlou, Mahdi Gouravani, Amene Saghazadeh, Nima Rezaei |
| 20 |
[GO] |
2021―Jun―07 |
Efficacy and safety of Dihydroorotate dehydrogenase (DHODH) inhibitors “Leflunomide” and “Teriflunomide” in Covid-19: A narrative review. |
Hardeep Kaur, Phulen Sarma, Anusuya Bhattacharyya, Saurabh Sharma, Neeraj Chhimpa, Manisha Prajapat, Ajay Prakash, Subodh Kumar, Ashutosh Singh, Rahul Singh, Pramod Avti, Prasad Thota, Bikash Medhi |
| 21 |
[GO] |
2021―May―17 |
Evaluation of Th1 and Th2 mediated cellular and humoral immunity in patients with COVID-19 following the use of melatonin as an adjunctive treatment |
Abdolkarim Hosseini, Hadi Esmaeili Gouvarchin Ghaleh, Hossein Aghamollaei, Mahdi Fasihi Ramandi, Gholamhossein Alishiri, Alireza Shahriary, Kazem Hassanpour, Mahdi Tat, Gholamreza Farnoosh |
| 22 |
[GO] |
2021―May―17 |
Azithromycin: Immunomodulatory and Antiviral Properties for SARS-CoV-2 Infection |
Mohammad Rafi Khezri, Naime Majidi Zolbanin, Morteza Ghasemnejad-berenji, Reza Jafari |
| 23 |
[GO] |
2021―May―15 |
Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity |
Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Yaaser Q. Almulaiky, Natália Cruz-Martins, Gaber El-Saber Batiha |
| 24 |
[GO] |
2021―Apr―03 |
Virtual high throughput screening: Potential Inhibitors for SARS-CoV-2 PLPRO and 3CLPRO Proteases |
Dhananjay Jade, Selvaraj Ayyamperumal, Vyshnavi Tallapaneni, Chandrasekar Moola Joghee Nanjan, Sagar Barge, Surender Mohan, Moola Joghee Nanjan |
| 25 |
[GO] |
2021―Mar―13 |
COVID-19 and IL-6: Why vitamin D (probably) helps but tocilizumab might not |
Morry Silberstein |
| 26 |
[GO] |
2021―Mar―02 |
Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19 |
Bertram Pitt, Nadia R. Sutton, Zhong Wang, Sascha N. Goonewardena, Michael Holinstat |
| 27 |
[GO] |
2021―Feb―25 |
Brief review on repurposed drugs and vaccines for possible treatment of COVID-19 |
Priyasha De, Ishita Chakraborty, Bhargavi Karna, Nirmal Mazumder |
| 28 |
[GO] |
2021―Feb―17 |
No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial |
Hamidreza Jamaati, Seyed MohammadReza Hashemian, Behrooz Farzanegan, Majid Malekmohammad, Payam Tabarsi, Majid Marjani, Afshin Moniri, Zahra Abtahian, Sara Haseli, Esmaeil Mortaz, Alireza Dastan, Abdolreza Mohamadnia, Abdolbaset Vahedi, Fatemeh Monjazebi, Fatemeh Yassari, Lida Fadaeizadeh, Ali Saffaei, Farzaneh Dastan |
| 29 |
[GO] |
2021―Feb―04 |
Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis |
Afra Rezagholizadeh, Sajad Khiali, Parvin Sarbakhsh, Taher Entezari-Maleki |
| 30 |
[GO] |
2021―Feb―03 |
Chloroquine: autophagy inhibitor, antimalarial, bitter taste receptor agonist in fight against COVID-19, a reality check? |
Pawan Sharma, Kielan D. McAlinden, Saeid Ghavami, Deepak A. Deshpande |
| 31 |
[GO] |
2021―Feb―03 |
COVID-19 infection and nanomedicine applications for development of vaccines and therapeutics: An overview and future perspectives based on polymersomes |
Mohammad A.I. Al-Hatamleh, Ma’mon M. Hatmal, Walhan Alshaer, Engku Nur Syafirah E.A. Rahman, Manali Haniti Mohd-Zahid, Dina M. Alhaj-Qasem, Chan Yean Yean, Iskandar Z. Alias, Juhana Jaafar, Khalid Ferji, Jean-Luc Six, Vuk Uskoković, Hiroshi Yabu, Rohimah Mohamud |
| 32 |
[GO] |
2021―Feb―02 |
SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study |
Krishnaprasad Baby, Swastika Maity, Chetan H. Mehta, Akhil Suresh, Usha Y. Nayak, Yogendra Nayak |
| 33 |
[GO] |
2021―Jan―27 |
Association of ACE inhibitors and Angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: a pathway-based analytical study |
R.A.H.U.L. Parit, S.R.I.D.H.A.R. Jayavel |
| 34 |
[GO] |
2021―Jan―23 |
Repositioning of histamine H1 receptor antagonist: Doxepin inhibits viropexis of SARS-CoV-2 Spike pseudovirus by blocking ACE2 |
Shuai Ge, Xiangjun Wang, Yajing Hou, Yuexin Lv, Cheng Wang, Huaizhen He |
| 35 |
[GO] |
2021―Jan―20 |
A review of potential suggested drugs for coronavirus disease (COVID-19) treatment |
Parastoo Tarighi, Samane Eftekhari, Milad Chizari, Mahsa Sabernavaei, Davod Jafari, Parastoo Mirzabeigi |
| 36 |
[GO] |
2021―Jan―10 |
Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic |
Sobia Noreen, Irsah Maqbool, Asadullah Madni |
| 37 |
[GO] |
2020―Dec―31 |
Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: Insights from atomistic simulations |
Aditya K. Padhi, Aniruddha Seal, Javed Masood Khan, Maqusood Ahamed, Timir Tripathi |
| 38 |
[GO] |
2020―Dec―18 |
Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel |
Zheng Zequn, W.U. Yujia, Q.I.A.N. Dingding, L.I.A.N. Jiangfang |
| 39 |
[GO] |
2020―Dec―01 |
Investigation of beta-lactoglobulin derived bioactive peptides against SARS-CoV-2 (COVID-19): in silico analysis |
Bilal Çakır, Betül Okuyan, Göksel Şener, Tuğba Tunalı-Akbay |
| 40 |
[GO] |
2020―Dec―01 |
Drug designing against NSP15 of SARS-COV2 via high throughput computational screening and structural dynamics approach |
Abida Batool, Nousheen Bibi, Farhat Amin, Mohammad Amjad Kamal |
| 41 |
[GO] |
2020―Nov―27 |
Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CLpro and PLpro), spike protein, RNA-dependent RNA polymerase (RdRp) and angiotensin-converting enzyme II receptor (ACE2) |
Chaima Mouffouk, Soumia Mouffouk, Sara Mouffouk, Leila Hambaba, Hamada Haba |
| 42 |
[GO] |
2020―Nov―25 |
COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies |
Kajal Rawat, Puja Kumari, Lekha Saha |
| 43 |
[GO] |
2020―Nov―20 |
A Comprehensive Review on Potential Therapeutics Interventions for COVID-19 |
Heerak Chugh, Amardeep Awasthi, Yashi Agarwal, Rajesh K. Gaur, Gagan Dhawan, Ramesh Chandra |
| 44 |
[GO] |
2020―Nov―20 |
A Review on Possible Mechanistic Insights of Nitazoxanide for Repurposing in COVID-19 |
Amit S. Lokhande, Padma V. Devarajan |
| 45 |
[GO] |
2020―Nov―20 |
An overview of viruses discovered over the last decades and drug development for the current Pandemic |
Agha Zeeshan Mirza, Hina Shamshad, Faisal Abdulrhman Osra, Turki M. Habeebullah, Moataz Morad |
| 46 |
[GO] |
2020―Nov―06 |
Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19 |
Himanshu G. Toor, Devjani I. Banerjee, Soumya Lipsa Rath, Siddhi A. Darji |
| 47 |
[GO] |
2020―Nov―03 |
Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead |
Harmanjit Singh, Prerna Chauhan, Ashish Kumar Kakkar |
| 48 |
[GO] |
2020―Nov―01 |
Functional and druggability analysis of the SARS-CoV-2 proteome |
Claudio N. Cavasotto, Maximiliano Sánchez Lamas, Julián Maggini |
| 49 |
[GO] |
2020―Oct―31 |
COVID-19 and antimalarials. Have we been doing it wrong all along? |
Cismaru Cosmin Andrei, Cismaru Gabriel Laurentiu, Nabavi Seyed Fazel, Nabavi Seyed Mohammad, Berindan-Neagoe Ioana |
| 50 |
[GO] |
2020―Oct―29 |
Unravelling high-affinity binding compounds towards transmembrane protease serine 2 enzyme in treating SARS-CoV-2 infection using molecular modelling and docking studies |
Pooja M, Gangavaram Jyothi Reddy, Kanipakam Hema, Sujatha Dodoala, Bharathi Koganti |
| 51 |
[GO] |
2020―Oct―29 |
In silico identification of strong binders of the SARS-CoV-2 receptor-binding domain |
Nouredine Behloul, Sarra Baha, Yuqian Guo, Zhifang Yang, Ruihua Shi, Jihong Meng |
| 52 |
[GO] |
2020―Oct―29 |
Science unites a troubled world: Lessons from the pandemic |
George W. Booz, Fouad A. Zouein |
| 53 |
[GO] |
2020―Oct―24 |
Recent progress of antiviral therapy for coronavirus disease 2019 |
Mengmeng Zhao, Jishou Zhang, Hanli Li, Zhen Luo, Jing Ye, Yao Xu, Zhen Wang, Di Ye, Jianfang Liu, Dan Li, Menglong Wang, Jun Wan |
| 54 |
[GO] |
2020―Oct―24 |
Screening Malaria-box compounds to identify potential inhibitors against SARS-CoV-2 Mpro using molecular docking and dynamics simulations studies |
Shahzaib Ahamad, Hema Kanipakam, Shweta Birla, Md Shaukat Ali, Dinesh Gupta |
| 55 |
[GO] |
2020―Oct―22 |
Gordian Knot: Gastrointestinal lesions caused by three highly pathogenic coronaviruses from SARS-CoV and MERS-CoV to SARS-CoV-2 |
Xiang Meng, Qiu-yue Lou, Wen-ying Yang, Ran Chen, Wen-hua Xu, Yang Yang, Lei Zhang, Tao Xu, Hui-fen Xiang |
| 56 |
[GO] |
2020―Oct―21 |
Translating bioactive peptides for COVID-19 therapy |
Khushwant S. Bhullar, Steven J. Drews, Jianping Wu |
| 57 |
[GO] |
2020―Oct―18 |
Renin angiotensin system at the interface of COVID-19 infection |
Rukhsana Gul, Kim Uh-Hyun, Assim A. Alfadda |
| 58 |
[GO] |
2020―Oct―13 |
Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic |
Ranjana Bhandari, Garima Khanna, Anurag Kuhad |
| 59 |
[GO] |
2020―Oct―13 |
Computational and theoretical exploration for clinical suitability of Remdesivir drug to SARS-CoV-2 |
Shaik Mahammad Nayeem, Ershad Mohammed Sohail, Gajjela Priyanka Sudhir, Munnangi Srinivasa Reddy |
| 60 |
[GO] |
2020―Oct―11 |
Treatment for COVID-19: An overview |
Cristina Stasi, Silvia Fallani, Fabio Voller, Caterina Silvestri |
| 61 |
[GO] |
2020―Oct―07 |
Targeting pivotal inflammatory pathways in COVID-19: A mechanistic review |
Akram Yarmohammadi, Mostafa Yarmohammadi, Sajad Fakhri, Haroon Khan |
| 62 |
[GO] |
2020―Oct―06 |
Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment |
Yan Wang, Lei Chen |
| 63 |
[GO] |
2020―Oct―04 |
Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19? |
Luis H.A. Costa, Bruna M. Santos, Luiz G.S. Branco |
| 64 |
[GO] |
2020―Oct―01 |
New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19 |
Manar Mohammed El Tabaa, Maram Mohammed El Tabaa |
| 65 |
[GO] |
2020―Sep―22 |
Integrative transcriptomics analysis of lung epithelial cells and identification of repurposable drug candidates for COVID-19 |
Tania Islam, Md Rezanur Rahman, Busra Aydin, Hande Beklen, Kazim Yalcin Arga, Md Shahjaman |
| 66 |
[GO] |
2020―Sep―19 |
A review of medications used to control and improve the signs and symptoms of COVID-19 patients |
Kiavash Hushmandi, Saied Bokaie, Mehrdad Hashemi, Ebrahim Rahmani Moghadam, Mehdi Raei, Farid Hashemi, Mahdi Bagheri, Solomon Habtemariam, Seyed Mohammad Nabavi |
| 67 |
[GO] |
2020―Sep―15 |
Corticosteroid therapy is associated with the delay of SARS-CoV-2 clearance in COVID-19 patients |
Rui Huang, Chuanwu Zhu, Leyang Xue, Chunyang Li, Xiaomin Yan, Songping Huang, Biao Zhang, Li Zhu, Tianmin Xu, Fang Ming, Yun Zhao, Juan Cheng, Huaping Shao, Xiang-an Zhao, Dawen Sang, Haiyan Zhao, Xinying Guan, Xiaobing Chen, Yuxin Chen, Jie Wei, Rahma Issa, Longgen Liu, Xuebing Yan, Chao Wu |
| 68 |
[GO] |
2020―Sep―15 |
Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic |
Faezeh Monji, Abrar Al-Mahmood Siddiquee, Farshad Hashemian |
| 69 |
[GO] |
2020―Sep―12 |
Possibility of magnesium supplementation for supportive treatment in patients with COVID-19 |
Chuan-Feng Tang, Hong Ding, Rui-Qing Jiao, Xing-Xin Wu, Ling-Dong Kong |
| 70 |
[GO] |
2020―Sep―12 |
COVID-19 associated complications and potential therapeutic targets. |
Jasmin D. Monpara, Srushti J. Sodha, Pardeep K. Gupta |
| 71 |
[GO] |
2020―Sep―12 |
Curcumin, a traditional spice component, can hold the promise against COVID-19? |
Vivek Kumar Soni, Arundhati Mehta, Yashwant Kumar Ratre, Atul Kumar Tiwari, Ajay Amit, Rajat Pratap Singh, Subash Chandra Sonkar, Navaneet Chaturvedi, Dhananjay Shukla, Naveen Kumar Vishvakarma |
| 72 |
[GO] |
2020―Sep―11 |
Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2 |
Upinder Kaur, Kumudini Acharya, Ritwick Mondal, Amit Singh, Luciano Saso, Sasanka Chakrabarti, Sankha Shubhra Chakrabarti |
| 73 |
[GO] |
2020―Sep―11 |
Macrophage responses associated with COVID-19: A pharmacological perspective |
George W. Booz, Raffaele Altara, Ali H. Eid, Zena Wehbe, Souha Fares, Hassan Zaraket, Nada J. Habeichi, Fouad A. Zouein |
| 74 |
[GO] |
2020―Sep―01 |
The prophylaxis and treatment potential of supplements for COVID-19 |
Adeleh Sahebnasagh, Fatemeh Saghafi, Razieh Avan, Amirhosein Khoshi, Masoud Khataminia, Mohammadreza Safdari, Solomon Habtemariam, Hassan Rezai Ghaleno, Seyed Mohammad Nabavi |
| 75 |
[GO] |
2020―Aug―22 |
Viroinformatics approach to explore the inhibitory mechanism of existing drugs repurposed to fight against COVID-19. |
Nousheen Bibi, Sana Gul, Johar Ali, Mohammad Amjad Kamal |
| 76 |
[GO] |
2020―Aug―22 |
Food proteins are a potential resource for mining cathepsin L inhibitory drugs to combat SARS-CoV-2 |
Ashkan Madadlou |
| 77 |
[GO] |
2020―Aug―20 |
Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial |
Daryoush Hamidi Alamdari, Ahmad Bagheri Moghaddam, Shahram Amini, Mohammad Reza Keramati, Azam Moradi Zarmehri, Aida Hamidi Alamdari, Mohammadamin Damsaz, Hamed Banpour, Amir Yarahmadi, George Koliakos |
| 78 |
[GO] |
2020―Aug―15 |
The potential effectiveness of acetazolamide in the prevention of acute kidney injury in COVID-19: A hypothesis |
Parham Habibzadeh, Mohammad Mofatteh, Saeid Ghavami, Jamshid Roozbeh |
| 79 |
[GO] |
2020―Aug―08 |
What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results |
Vanessa Aparecida Marcolino, Tatiana Colombo Pimentel, Carlos Eduardo Barão |
| 80 |
[GO] |
2020―Aug―06 |
COVID-19: A review of the proposed pharmacological treatments |
Sarah Lam, Andrew Lombardi, Aviv Ouanounou |
| 81 |
[GO] |
2020―Aug―06 |
In silico pharmacokinetic and molecular docking studies of natural flavonoids and synthetic indole chalcones against essential proteins of SARS-CoV-2 |
Balaji Gowrivel Vijayakumar, Deepthi Ramesh, Annu Joji, Jayadharini Jayachandra prakasan, Tharanikkarasu Kannan |
| 82 |
[GO] |
2020―Aug―05 |
Coronavirus diseases 2019: Current biological situation and potential therapeutic perspective |
Suliman Khan, Huseyin Tombuloglu, Sameh E. Hassanein, Surya Rehman, Ayhan Bozkurt, Emre Cevik, Shaimaa Abdel-Ghany, Ghulam Nabi, Ashaq Ali, Hussein Sabit |
| 83 |
[GO] |
2020―Aug―04 |
Molecular effects and retinopathy induced by hydroxychloroquine during SARS-CoV-2 therapy: Role of CYP450 isoforms and epigenetic modulations |
Alireza Paniri, Mohammad Mahdi Hosseini, Ahmad Rasoulinejad, Haleh Akhavan-Niaki |
| 84 |
[GO] |
2020―Aug―03 |
In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2 |
Rujuta R. Deshpande, Arpita Pandey Tiwari, Narendra Nyayanit, Manisha Modak |
| 85 |
[GO] |
2020―Aug―01 |
An overview of the pathogenic mechanisms involved in severe cases of COVID-19 infection, and the proposal of salicyl-carnosine as a potential drug for its treatment |
Alexander V. Lopachev, Rogneda B. Kazanskaya, Anastasiya V. Khutorova, Tatiana N. Fedorova |
| 86 |
[GO] |
2020―Jul―31 |
Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection |
Gayathri Krishna, Vinod Soman Pillai, Mohanan Valiya Veettil |
| 87 |
[GO] |
2020―Jul―31 |
Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting |
Sourena Sharifkashani, Melika Arab Bafrani, Alireza Soltani Khaboushan, Marzieh Pirzadeh, Ali Kheirandish, Hanie Yavarpour_Bali, Amirhossein Hessami, Amene Saghazadeh, Nima Rezaei |
| 88 |
[GO] |
2020―Jul―25 |
OUTBREAK of novel corona virus disease (COVID-19): Antecedence and aftermath |
Ankit Awasthi, Sukriti Vishwas, Leander Corrie, Rajesh Kumar, Rubiya Khursheed, Jaskiran Kaur, Rajan Kumar, K.R. Arya, Monica Gulati, Bimlesh Kumar, Sachin Kumar Singh, Narendra Kumar Pandey, Sheetu Wadhwa, Pardeep Kumar, Bhupinder Kapoor, Rajneesh Kumar Gupta, Ankit Kumar |
| 89 |
[GO] |
2020―Jul―17 |
Virology, pathogenesis, diagnosis and in-line treatment of COVID-19 |
Pavan Kumar Samudrala, Pramod Kumar, Kamlesh Choudhary, Nagender Thakur, Gaurav Suresh Wadekar, Richa Dayaramani, Mukta Agrawal, Amit Alexander |
| 90 |
[GO] |
2020―Jul―17 |
Advances in the possible treatment of COVID-19: A review. |
Pankaj Chibber, Syed Assim Haq, Irfan Ahmed, Nusrit Iqbal Andrabi, Gurdarshan Singh |
| 91 |
[GO] |
2020―Jul―15 |
Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know? |
Antonio Vitiello, Francesco Ferrara |
| 92 |
[GO] |
2020―Jul―04 |
Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus |
Calvin A. Omolo, Nikki Soni, Victoria Oluwaseun Fasiku, Irene Mackraj, Thirumala Govender |
| 93 |
[GO] |
2020―Jun―30 |
Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19 |
Mohamed A. El-Missiry, Ziad M.A. El-Missiry, Azza I. Othman |
| 94 |
[GO] |
2020―Jun―27 |
Drug treatment of coronavirus disease 2019 (COVID-19) in China. |
Zhe Jin, Jing-Yi Liu, Rang Feng, Lu Ji, Zi-Li Jin, Hai-Bo Li |
| 95 |
[GO] |
2020―Jun―27 |
Current pharmacological treatments for SARS-COV-2: A narrative review |
Giulio Nittari, Graziano Pallotta, Francesco Amenta, Seyed Khosrow Tayebati |
| 96 |
[GO] |
2020―Jun―17 |
Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management? |
Antoni Sureda, Javad Alizadeh, Seyed Fazel Nabavi, Ioana Berindan Neagoe, Cosmin Andrei Cismaru, Philippe Jeandet, Marek J. Los, Emilio Clementi, Seyed Mohammad Nabavi, Saeid Ghavami |
